Levi & Korsinsky Alerts Ardelyx Investors About Class Action Deadline

Latest Insights on the Ardelyx Class Action Lawsuit

Levi & Korsinsky, LLP has launched a significant class action lawsuit against Ardelyx, Inc., listed on NASDAQ as ARDX. This legal action has been initiated specifically for shareholders who acquired securities between January 13, 2025, and August 6, 2026. The firm is urging affected investors to determine their eligibility for financial recovery through this lawsuit.

Background of the Case
The lawsuit centers around claims that Ardelyx misrepresented critical information regarding its management of payer utilization and prescription processes, which allegedly impeded new patient initiations for its drug IBSRELA. Despite the company's earlier affirmation of a revenue guidance set between $240 million to $250 million for 2025, the projected earnings were later revised downward.

On August 6, 2026, Ardelyx's shares dropped from $4.87 to $4.00, marking a substantial decline of about 18%. This stock price decrease followed the announcement that the company had reduced its full-year revenue projections for IBSRELA and had withdrawn long-term revenue expectations for XPHOZAH, citing intensified payer management issues. This sharp pivot raised critical questions about whether shareholders had been adequately informed regarding the impacts of external management controls on sales performance.

Details of Allegations
The class action outlines that Ardelyx failed to disclose how increased management regulations were significantly affecting new-patient starts. Although the company highlighted a remarkable 57% growth in IBSRELA sales earlier in the year, it neglected to communicate how stringent prior authorization requirements were already elongating the process from prescription to filled script.

The filing cites various statistics to illustrate the alleged discrepancies in revenue expectations and actual performance. For example:

- The U.S. net product sales for 2024 stood at approximately $319 million, shared almost equally between IBSRELA and XPHOZAH.
- Ardelyx initially reaffirmed ambitious sales targets of exceeding $1 billion for IBSRELA and $750 million for XPHOZAH.

In light of these circumstances, Joseph E. Levi, the lead attorney at Levi & Korsinsky, emphasized that the firm seeks to hold Ardelyx accountable for any misleading statements and assurances provided to investors.

What Can Affected Investors Do?
Investors who bought shares during the time in question and experienced losses now have an opportunity to act. They can contact Levi & Korsinsky via email or telephone to learn if they qualify as lead plaintiffs in this case. Important steps involve gathering brokerage records to document purchases and sales, which can aid in evaluating potential recovery.

For those who sold their shares, eligibility hinges on the timing of purchases, not on current holdings. Even if shares were sold post-purchase at a loss, individuals may still pursue compensation.

Next Steps for Investors
The deadline for filing motions to be considered as lead plaintiff is set for November 16, 2026. This is crucial for any investor wishing to actively partake in the legal proceedings. The overarching goal of the lawsuit is to seek justice for impacted Ardelyx shareholders, aiming to recover losses attributed to the alleged misinformation by the company.

Buyers of Ardelyx securities during the class period who wish to evaluate their eligibility and potential claim can do so through a no-cost assessment from Levi & Korsinsky. This process is contingent on court approvals, ensuring no upfront costs to investors involved in the class lawsuit.

Ardelyx stands at a critical juncture, and affected investors are encouraged to stay informed and engaged throughout the unfolding of this significant class action lawsuit.